Request Demo

Last update 13 Sep 2025

Quetiapine Fumarate

Last update 13 Sep 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol, Quetiapine, Quetiapine Famarate

+ [25]

Target

5-HT2A receptor x D2 receptor

Action

antagonists

Mechanism

5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Inactive Indication

Acute schizophreniaAgitationAlcoholism+ [22]

Originator Organization

AstraZeneca Pharmaceuticals Co. Ltd.

Active Organization

CHEPLAPHARM Arzneimittel GmbH

Astellas Pharma, Inc.

Luye Pharma Group Ltd.

+ [5]

Inactive Organization

AstraZeneca PLCUS Department of Veterans Affairs (District of Columbia)

Forest Laboratories LLC

License Organization

M8 Holdings LLC

Luye Pharma Group Ltd.

Kyowa Pharmaceutical Industry Co., Ltd.

+ [13]

Drug Highest PhaseApproved

First Approval Date

United States (26 Sep 1997),

Bipolar DisorderSchizophrenia

RegulationPriority Review (China)

Structure/Sequence

Molecular FormulaC46H54N6O8S2

InChIKeyZTHJULTYCAQOIJ-WXXKFALUSA-N

CAS Registry111974-72-2

479

Clinical Trials associated with Quetiapine Fumarate

NCT07047651

/ RecruitingPhase 4IIT

The Effectiveness and Efficacy of the Combination of Pharmacotherapy With the Two New Recovery-oriented Programs, RECOVERYTRSGR (Treatment Resistant Schizophrenia) and RECOVERYTRSBDGR (Treatment Resistant Bipolar Disorder)

The effectiveness and efficacy of the combination of pharmacotherapy with the two new recovery-oriented programs, RECOVERYTRSGR for patients with treatment- resistant schizophrenia and RECOVERYTRSBDGR for patients with treatment- resistant bipolar disorder.

Start Date04 Jun 2025

Sponsor / Collaborator-

ISRCTN16864220

/ RecruitingPhase 3IIT

The clinical and cost effectiveness of quetiapine for people with borderline personality disorder: A pragmatic, double-blind, placebo-controlled, randomised trial

Start Date31 May 2025

Sponsor / Collaborator

The University of Liverpool

NCT05603104

/ RecruitingPhase 3IIT

A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros. When diagnosed with one of these disorders, patients are prescribed psychotropic medication such as antidepressants, mood stabilisers or antipsychotics. It is unknown whether this first-line treatment will be successful. After this first-line treatment fails, usually a second-line treatment is initiated, and when this is not successful either a third-line treatment is initiated. Third-line treatments are quite successful, especially when compared to second-line treatments. The research question is whether the third-line treatments (early-intensified treatments) would be more efficacious than the current second-line treatments (treatment as usual) for schizophrenia, bipolar and major depressive disorders. If this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments and adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs.

Start Date27 Apr 2025

Sponsor / Collaborator

Universität Leipzig

100 Clinical Results associated with Quetiapine Fumarate

100 Translational Medicine associated with Quetiapine Fumarate

100 Patents (Medical) associated with Quetiapine Fumarate

8,188

Literatures (Medical) associated with Quetiapine Fumarate

01 Jan 2026·JOURNAL OF AFFECTIVE DISORDERS

Is there a gap between improved symptoms and restored functioning in adults with bipolar II disorder?

Article

Author: Swartz, Holly A ; Early, Theresa J ; Tabone, Jiyoung K ; Bailey, Bridget C ; Leber, Alanna ; Wen, Sijin

AIMS:

This study examined differences in syndromal recovery, symptom improvement, and functional recovery over time in patients with bipolar II disorder (BD II), and how these varied by treatment and functioning domain.

METHODS:

Patients with BD II, currently depressed (N = 92) were randomly assigned to 20 weeks of Interpersonal and Social Rhythm Therapy (IPSRT) with placebo (IPSRT+P) or quetiapine (IPSRT+Q). Hamilton Rating Scale for Depression, Young Mania Rating Scale, and Functional Assessment Short Test were administered at weeks one, 8, 12, and 20-week follow-up. Syndromal recovery (remission), symptom improvement (50 % improvement in depressive symptoms), and functional recovery (restored functioning) were coded as binary outcomes. Longitudinal generalized linear mixed-effects models examined differences across the three outcomes over time.

RESULTS:

Functional recovery was significantly less likely to occur at all time points than symptom improvement (p < 0.01). At weeks 12 and 20, all functional recovery subdomains were less likely to occur than symptom improvement (p ≤ 0.01), except for leisure (NS). At week 8, functional recovery was more likely to occur than syndromal recovery (p = 0.01); however, this difference was not sustained at weeks 12 and 20. Differences across groups did not vary by treatment (NS) or number of previous mood episodes (NS).

CONCLUSIONS:

Most patients with BD II depression showed significant improvement in depressive symptoms regardless of treatment assignment indicating that some patients can be treated with IPSRT monotherapy for depressive symptoms. Yet, the majority did not achieve functional recovery. These findings highlight the importance of prioritizing patient defined recovery in addition to considerations of symptomatic improvement in BD II treatment.

31 Dec 2025·Dialogues in Clinical Neuroscience

Antipsychotic off-label use in the 21st century: An enduring public health concern

Review

Author: Verdoux, Hélène

Soon after the introduction of second-generation antipsychotics, antipsychotic off-label use (OLU) progressively became a common prescribing practice. This evolving practice should be regularly monitored considering the growing number of persons exposed to the adverse effects of antipsychotics. The aim of the present review was to synthesise the literature published over the last 15 years on antipsychotic OLU for mental health symptoms. Observational studies confirm the persisting high rate of antipsychotic OLU prescription in two out of three youths and 30-60% of adults using antipsychotics. Increasing rates of low-dose quetiapine prescriptions for anxiety or sleep symptoms are paradigmatic of the current public health concern regarding antipsychotic OLU. Such prescriptions receive impetus from industry-funded marketing strategies and prescribers' feeling of innocuousness, with a resulting underestimation of the risk of adverse drug reactions (ADR). However, antipsychotic OLU should be neither trivialised nor demonised since it may be the only therapeutic option in persons with resistant psychiatric disorders or serious ADR with labelled drugs. To reduce the populational impact of antipsychotic OLU, it is necessary to better control the influence of the pharmaceutical industry regarding newly marketed drugs and to better inform prescribers and users about the risks associated with OLU prescribing.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsychotics or versus quetiapine

Article

Author: Chrones, Lambros ; Gopal, Daksha ; Doshi, Dilesh ; Rajagopalan, Krithika ; Rashid, Nazia

BACKGROUND:

Pimavanserin (PIM) is the only FDA approved atypical antipsychotic treatment (AAP) for hallucinations and delusions associated with Parkinson's disease psychosis (PDP) among patients with or without coexisting dementia; however, Other-AAPs (i.e. quetiapine (QUE), risperidone, olanzapine, aripiprazole) are commonly prescribed off-label. Healthcare resource utilization (HCRU) patterns among patients with PDP and coexisting dementia (PDP+D) who newly initiate PIM versus (vs.) Other-AAPs (i.e. other AAP-mix) or QUE in real-world settings is limited.

METHODS:

A retrospective analysis of Parts A, B, and D claims from the 100% Medicare sample from 04/01/15 to 12/31/21 was conducted. AAP-naïve patients with PDP+D who initiated ≥12-month continuous monotherapy with PIM vs. Other-AAPs or vs. QUE during 04/01/16-12/31/20 were propensity score matched 1:1 on thirty-one variables (age, sex, race, region and 27 Elixhauser comorbidity characteristics). Adjusted log binomial regressions compared all-cause HCRU [(e.g. inpatient hospitalizations and by hospitalization-type [short-term stays (ST-stays), long-term stays (LT-stays), skilled nursing facility stays (SNF-stays)], and emergency room (ER) visits] risk between cohorts.

RESULTS:

Of the 5,932 patients with PDP+D, matched cohorts (n = 1,294 in each) on continuous- monotherapy of PIM vs. Other-AAPs or QUE had similar demographics and comorbidities. Adjusted regression results showed those who initiated PIM vs. Other-AAPs had significantly lower relative risk (RR) of ≥1 all-cause inpatient hospitalizations (RR = 0.88, 95% CI: 0.80-0.97), ST-stays (RR = 0.86, 95% CI: 0.77-0.95), SNF-stays (RR = 0.79, 95% CI: 0.68-0.92), and ER visits (RR = 0.89, 95% CI: 0.84-0.94). PIM vs. QUE also experienced significantly lower RR for ≥1 all-cause IP hospitalizations (RR = 0.88, 95% CI: 0.80-0.96), ST-stays (RR = 0.85, 95% CI: 0.77-0.95), SNF-stays (RR = 0.81, 95% CI: 0.70-0.94), and ER visits (RR = 0.88, 95% CI: 0.83-0.94).

CONCLUSIONS:

Patients initiating PIM-monotherapy for PDP+D experienced 12% lower all-cause inpatient hospitalizations vs. Other-AAPs or QUE. These results are consistent with prior real-world research in PDP with or without dementia.

News (Medical) associated with Quetiapine Fumarate

28 Jul 2025

·www.prnewswire.com

Standard drug screening fails to identify some children who have been exposed to substances in unsafe home environments

New findings at ADLM 2025 could remedy this CHICAGO, July 28, 2025 /PRNewswire/ -- According to research presented today at ADLM 2025 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), standard drug screening misses low concentrations of targeted substances in around 5% of urine samples taken from patients under age 18, suggesting that children with drugs in their systems are sometimes released from healthcare settings into unsafe home environments. The study highlights an adjustment that clinical labs can make to improve the accuracy of results and to help ensure that substance-exposed children and their families get appropriate support. Researchers have long known that standard urine drug screening (UDS) — which is typically done using a technique known as immunoassay — can sometimes trigger false positives, or erroneous results that indicate the presence of a drug when there isn't one. It's the reason a second confirmatory test with mass spectrometry is typically used to verify results for patients who test positive on immunoassay. However, the opposite issue, where UDS indicates an absence of drugs in patients who have actually taken them (false negatives), has not been well studied. This mistake is more likely to occur in samples taken from infants and young children whose kidneys are still developing or who have incidental exposure to a low level of drugs, resulting in a low drug concentration in their urine that may not reach the cutoff used in standard UDS. One approach for minimizing this possibility is to use mass spectrometry on all pediatric patients, skipping the initial immunoassay. "To our knowledge, St. Louis Children's is the only hospital in the U.S. to adopt this 'direct-to-mass-spectrometry' approach," said Dr. Yanchun Lin, one of the study's authors and a clinical chemistry fellow at Washington University in Saint Louis, Missouri. "So we really want to urge laboratorians to reconsider the approach they adopt for pediatric UDS testing." The researchers used two strategies to compare immunoassay results with mass spectrometry for detecting substances in common drug tests, including amphetamine/methamphetamine, cocaine/benzoylecgonine (the main metabolite of cocaine), THC, opiates, fentanyl, benzodiazepines, and methadone. In the first approach, they studied 125 urine samples over a 5-month period from pediatric patients with weakly positive results on mass spectrometry to check how many of them were missed by immunoassay (forward approach). For the second strategy, they assessed 115 urine samples that tested negative on immunoassay to assess if mass spectrometry could detect any drugs (reverse approach). Among the 125 samples that tested positive on mass spectrometry, 112 (approximately 90%) contained compounds not detected by immunoassay, most commonly methamphetamine and benzoylecgonine. Thirty-eight (33%) of the 115 samples found negative on routine UDS tested positive for at least one substance when re-examined by mass spectrometry. Moreover, mass spectrometry identified substances in six samples (5%) that were targeted but missed by immunoassay. In addition, the researchers identified 32 pediatric urine samples that contained prescription medications not picked up by immunoassay, including lorazepam, ketamine, bupropion, methylphenidate, clonidine, quetiapine, venlafaxine, and naloxone. They also found five samples containing fentanyl, which wasn't on the UDS menu at some study centers from which samples were taken. Taken together, the results indicate that UDS may miss low drug concentrations in approximately 1 in 20 pediatric urine samples. This finding held true using both the forward and reverse schemes, spanning multiple clinical environments and analytic platforms. Using a direct-to-mass spectrometry approach would significantly lessen the risk of false-negative drug screens and largely eliminate false-positive findings as well, the authors conclude. That said, making this change isn't without challenges for labs. "It's actually pretty labor intense," Lin said, "and it's much harder to maintain the assay" using the direct-to-mass spectrometry approach. "You need highly trained personnel and dedicated full-time employees," she added. But labs that can make the shift will benefit from more accurate results that could translate to better care. "If it's possible, it should definitely be adopted, especially for pediatric patients," Lin said. Session information ADLM 2025 registration is free for members of the media. Reporters can register online here: Abstract A-349: False-negative immunoassay drug screens uncovered with a direct to mass spectrometry approach in a pediatric population will be presented during: Student poster competition Monday, July 28 9:30 a.m. – 4 p.m. Room S405 Scientific poster session Tuesday, July 29 9:30 a.m. – 5 p.m. (presenting authors in attendance from 1:30 – 2:30 p.m.) Poster Hall on the Expo show floor Both sessions will take place at McCormick Place, Chicago. About ADLM 2025 ADLM 2025 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo) offers 5 days packed with opportunities to learn about exciting science from July 27-31 in Chicago. Plenary sessions will explore urgent problems related to clinical artificial intelligence (AI) integration, fake medical news, and the pervasiveness of plastics, as well as tapping into the promise of genomics and microbiome medicine for personalized healthcare. At the ADLM 2025 Clinical Lab Expo, more than 800 exhibitors will fill the show floor of the McCormick Place Convention Center in Chicago, with displays of the latest diagnostic technology, including but not limited to AI, point-of-care, and automation. About the Association for Diagnostics & Laboratory Medicine (ADLM) Dedicated to achieving better health for all through laboratory medicine, ADLM (formerly AACC) unites more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from 110 countries around the world. Our community is at the forefront of laboratory medicine's diverse subdisciplines, including clinical chemistry, molecular diagnostics, mass spectrometry, clinical microbiology, and data science, and is comprised of individuals holding the spectrum of lab-related professional degrees, certifications, and credentials. Since 1948, ADLM has championed the advancement of laboratory medicine by fostering scientific collaboration, knowledge sharing, and the development of innovative solutions that enhance health outcomes. For more information, visit . Christine DeLong ADLM Director, Editorial and Media Relations (p) 202.835.8722 [email protected] Bill Malone ADLM Senior Director, Strategic Communications (p) 202.835.8756 [email protected] SOURCE Association for Diagnostics & Laboratory Medicine (ADLM) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultClinical Study

31 May 2025

·pharma.economictimes.indiatimes.com

AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action

London: Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of scheming to delay a generic version of its schizophrenia drug Seroquel, causing companies to pay artificially higher prices. The plaintiffs, a group of drug purchasers including Smith Drug Co and KPH Healthcare Services, filed the preliminary settlement on Thursday in the U.S. District Court for the District of Delaware. The deal requires approval from U.S. District Judge Colm Connolly. The 2019 lawsuit alleged AstraZeneca schemed with Handa Pharmaceuticals to delay the marketing of a generic version of Seroquel XR, which is used to treat schizophrenia and bipolar disorder. Handa said it will pay $494,000 to settle the buyers' claims. A trial had been scheduled for May 5. AstraZeneca declined to comment. Handa and a lead attorney for the plaintiffs did not immediately respond to requests for comment. AstraZeneca and Handa denied any wrongdoing in agreeing to settle. They said the resolution avoids the expense and distraction of any further litigation. Worldwide annual sales of Seroquel once topped $5.3 billion. The class period covers business purchases from 2015 to 2017. In their settlement filing, the plaintiffs' attorneys called the amount an "outstanding" result for the class of drug buyers. The plaintiffs' lawyers said they would seek up to 36% of the settlement fund for legal fees, or about $18.5 million. AstraZeneca in 2010 agreed to pay $520 million to the U.S. government to settle claims that the company illegally marketed and promoted Seroquel for unapproved uses. The company in 2011 paid $68.5 million to resolve U.S. states' claims over the alleged deceptive marketing of the drug. The case is In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation, U.S. District Court for the District of Delaware, No. 1:20-cv-01076-CFC. For direct purchasers: Jonathan Gerstein of Garwin Gerstein & Fisher For AstraZeneca: Benjamin Greenblum of Williams & Connolly For Handa: James Gallagher of Davis Malm & D'Agostine Read more: Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case 20 US states balk at Florida settlement with drugmaker Sandoz Mylan to pay $73.5 mln to settle drug wholesalers' EpiPen antitrust claims (Reporting by Mike Scarcella)

Patent Infringement

16 Mar 2025

·pharma.economictimes.indiatimes.com

Allchem Lifescience files IPO papers with Sebi; aims to raise Rs 190-cr via fresh issue

New Delhi: Drug maker Allchem Lifescience has filed preliminary papers with markets regulator Sebi seeking its approval to raise funds through an initial public offering ( IPO ). The Gujarat-based company's proposed IPO comprises fresh issue of equity shares aggregating up to Rs 190 crore and an offer for sale (OFS) of 71.55 lakh equity shares by promoters, according to the draft red herring prospectus (DRHP). Those selling shares in the OFS are Kantilal Ramanlal Patel and Manisha Bipin Patel. At present, promoters and promoter group entities hold 100 per cent stake in the company. In its draft papers filed on Friday, Allchem Lifescience proposes to utilise proceeds from the fresh issue worth Rs 130 crore towards debt payment, while a portion will be used for general corporate purposes as well as to support the business requirements of the company. Incorporated in 2017, Allchem Lifescience is an Indian manufacturer of active pharmaceutical ingredients (API) intermediates and speciality chemicals. It specialises in the production of key starting materials (KSMs), generic API intermediates and specialty chemicals. The company is a key player in manufacturing piperazine derivatives, which are critical raw materials for producing APIs like quetiapine, which is used in treating schizophrenia and bipolar disorder. Over the years, Allchem Lifescience has developed the ability to manufacture 263 products which demonstrates their strong focus on different chemistries in organic chemical compounds. The company's focus has been to identify potential demand for products, in particular, products that are difficult to source in India or which being import substitutes are not easily available, develop such products and scale up production once the demand is in place. The company has a manufacturing facility in Vadodara, Gujarat. Allchem Lifescience caters to prominent domestic and international customers, including Alembic Pharmaceuticals , Bond Chemical, Indoco Remedies , Micro Labs, MSN Laboratories, Nagase India, Neogen Chemicals , Neuland Laboratories , and Unichem Laboratories . As of December 2024, the company served customers across 13 states in India and 22 countries overseas. As of FY24, it had 148 customers in India and 66 customers overseas. On the financial front, the company's revenue from operations has grown at a compound annual growth rate (CAGR) of 12.75 per cent between FY22 and FY24. The revenue figures for the six months ended September 30, 2024 was at Rs 7.84 crore. Additionally, the profit after tax (PAT) has grown at a CAGR of 28.65 per cent from March 31, 2022, to March 31, 2024. The PAT figures for the six-month ended September 2024 stood at Rs 1.09 crore. Emkay Global Financial Services is the sole book-running lead managers to the issue.

Financial StatementIPO

100 Deals associated with Quetiapine Fumarate

External Link

KEGG	Wiki	ATC	Drug Bank
D00458	Quetiapine Fumarate	N05AH04	DB01224

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bipolar and Related Disorders	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	03 Jul 2017
Depressive Disorder, Major	United States	CHEPLAPHARM Arzneimittel GmbH	02 Dec 2009
Bipolar Disorder	United States	CHEPLAPHARM Arzneimittel GmbH	26 Sep 1997
Schizophrenia	United States	CHEPLAPHARM Arzneimittel GmbH	26 Sep 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Marijuana Abuse	Phase 3	Germany	AstraZeneca PLC	01 Sep 2009
Endogenous depression	Phase 3	Spain	AstraZeneca PLC	01 May 2009
Depressive Disorder, Treatment-Resistant	Phase 3	Australia	AstraZeneca PLC	01 Nov 2008
Depressive Disorder, Treatment-Resistant	Phase 3	Austria	AstraZeneca PLC	01 Nov 2008
Depressive Disorder, Treatment-Resistant	Phase 3	Belgium	AstraZeneca PLC	01 Nov 2008
Depressive Disorder, Treatment-Resistant	Phase 3	Bulgaria	AstraZeneca PLC	01 Nov 2008
Depressive Disorder, Treatment-Resistant	Phase 3	Denmark	AstraZeneca PLC	01 Nov 2008
Depressive Disorder, Treatment-Resistant	Phase 3	Germany	AstraZeneca PLC	01 Nov 2008
Depressive Disorder, Treatment-Resistant	Phase 3	Hungary	AstraZeneca PLC	01 Nov 2008
Depressive Disorder, Treatment-Resistant	Phase 3	Italy	AstraZeneca PLC	01 Nov 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01858948 (CTgov)	Phase 3	Bipolar Disorder \| Metabolic Syndrome	19	Placebo+Quetiapine fumarate	pnefxhocwz(gncntiirkx) = zqejsmxocc tiprvwwzuv (yjlbrycrjm, 7.4) View more	-	25 Nov 2022
NCT02845453 (CTgov)	Phase 4	Bipolar Disorder \| Substance Abuse	24	Quetiapine (Quetiapine)	mflhiziwxc(yligpevqlt) = awfssugvdy ulzasgpdvj (jgufrsejrj, 6.9) View more	-	18 Apr 2022
				Placebo (Placebo)	mflhiziwxc(yligpevqlt) = oorlytvwbi ulzasgpdvj (jgufrsejrj, 6) View more
NCT00688818 (Pubmed \| J Clin Psychiatry)	Not Applicable	Depressive Disorder \| Anxiety Disorders Add-on	76	Quetiapine XR	lvqrhavzcw(zrzhkhbsgj) = tivewzuwrl nrqqgqgtfv (qeyhuosfvb, -7.41 to -0.64) View more	Positive	21 Mar 2022
NCT03568500 (CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	44	Digital Medicine System+Aripiprazole (Aripiprazole)	huuzeaqffu(gvlbdlvibg) = mpuwullhar hwhiwgtwbq (ztpewzzpul, rjfwqupjtx - ecxsdylaiz) View more	-	16 Jul 2020
				Digital Medicine System+Olanzapine (Olanzapine)	huuzeaqffu(gvlbdlvibg) = gkjdbjbktc hwhiwgtwbq (ztpewzzpul, wttazcucte - eylfmmwmxb) View more
NCT00579280 (CTgov)	Phase 4	Bipolar Disorder \| Panic \| Panic Disorder ... View more	224	quetiapine SR (Quetiapine SR)	kgevpjpndo(mseaajnyzr) = xtbknwgxka amgdpstvmw (qdonxabrhh, 0.62) View more	-	11 Jun 2020
				divalproex sodium ER (Divalproex Sodium ER)	kgevpjpndo(mseaajnyzr) = ffkavidrah amgdpstvmw (qdonxabrhh, 0.63) View more
NCT01725308 (Pubmed \| Clin Ther)	Phase 2/3	Bipolar Disorder	322	Quetiapine XR 150 mg	fzwajqxldl(kjzzgbwwji) = cwxrfulmqh naftacwtqj (wihhrayyyq )	-	06 Jun 2020
				Quetiapine XR 300 mg	fzwajqxldl(kjzzgbwwji) = lwuqenfadx naftacwtqj (wihhrayyyq )
NCT01119014 (TEA, Pubmed \| J Am Acad Child Adolesc Psychiatry)	Phase 4	Psychotic Disorders	113	Quetiapine-Extended Release	zxwzvsudrb(gdspdcnrew) = ovmppgyhkt xnlqbarrcd (niwikulldh, 3.92 - 5.83)	Negative	01 Nov 2019
				Aripiprazole	zxwzvsudrb(gdspdcnrew) = raijnxvuhy xnlqbarrcd (niwikulldh, 0.97 - 2.97)
NCT00515723 (Glulipid, CTgov)	Not Applicable	Diabetes Mellitus, Type 2 \| Schizoaffective disorder \| Schizophrenia ... View more	96	Olanzapine (Olanzapine)	dsifpgrbka(kbnbsfdiht) = igyqzvtela eeckawbqsf (gygygtrtbf, 2.48) View more	-	02 Oct 2019
				risperidone (Risperidone)	dsifpgrbka(kbnbsfdiht) = jnyrvdkqoi eeckawbqsf (gygygtrtbf, 2.64) View more
NCT00518973 (CTgov)	Not Applicable	Anorexia Nervosa	21	Placebo (Placebo)	udsayedsll(cjxkaovpnk) = azkeaqpzkt ymbrmofhow (ymvggfadwq, NA) View more	-	17 Jul 2019
				Quetiapine (Quetiapine)	udsayedsll(cjxkaovpnk) = ngkjcafkjw ymbrmofhow (ymvggfadwq, NA) View more
NCT00457366 (CTgov)	Phase 4	Agitation	72	Quetiapine	ixkqixhzkd(ryrnmsiypl) = yogmhyinra snuzmsqrvs (xfgnzekcke, 0.69) View more	-	05 Jul 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Quetiapine Fumarate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation